Next-generation sequencing (NGS) has the potential to revolutionize HIV resistance genotyping by lowering the threshold that rare but clinically significant HIV variants can be detected. NGS can also confer improved cost-effectiveness in high-throughput scenarios. We are very experience on using Illumina MiSeq instrument for clinical HIV genotyping and have produced over 1,000 genotypes.
Please note that academic price involves subsidizing the production of data and KRISP members producing (max. two individuals) and/or analyzing data are normally co-authors to manuscripts. The commercial price include all costs and no-authorship or collaborationn is needed. Price can vary due to exchange rates, price last estimated at - 2018-05-21